Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

January 28, 2021

Study Completion Date

January 13, 2022

Conditions
Squamous Cell Carcinoma of the Hypopharynx Stage IIISquamous Cell Carcinoma of the Hypopharynx Stage IVSquamous Cell Carcinoma of the Larynx Stage IIISquamous Cell Carcinoma of the Larynx Stage IVSquamous Cell Carcinoma of the Oropharynx Stage IIISquamous Cell Carcinoma of the Oropharynx Stage IVSquamous Cell Carcinoma of the Oral Cavity Stage IIISquamous Cell Carcinoma of the Oral Cavity Stage IV
Interventions
DRUG

Docetaxel

75 mg/m² on day 1 of 21-days cycle

DRUG

Cisplatin

75 mg/m² on day 1 of 21-days cycle

DRUG

5-fluorouracil

750 mg/m² day 1 to 5 during 24 hours of 21-days cycle

BIOLOGICAL

Cetuximab Induction

weekly, starting with 400 mg/m² during 120 min.(saturation) then continuing with 250 mg/m²; duration 3 cycles with 21 days

BIOLOGICAL

Cetuximab Radioimmunotherapy

weekly, starting with 400 mg/m² during 120 min.(saturation only arm A) then continuing with 250 mg/m²; duration 7 weeks

RADIATION

Boost irradiation

First 18 irradiations once daily with single dose of 1,8 Gy for 5 days per week. In addition by day 19 a second irradiation boost will be applied for further 12 days(1,5 Gy per day with at least 5 hours interval to 1,8 Gy dose. This results in total clinical target dose of 72 Gy and total subclinical target dose of 54 Gy. Duration of irradiation: 6 weeks

Trial Locations (8)

1140

Hanusch Krankenhaus Wien, Vienna

5020

PMU Salzburg, Salzburg

A-6807

Landeskrankenhaus Feldkirch, Feldkirch

A-3500

Landesklinikum Krems, Krems

A-4010

Krankenhaus d. Barmherzigen Schwestern Linz, Linz

A-4021

Kepler Universitätsklinikum, Med Campus III. Klinik für Interne 3 - Schwerpunkt Hämatologie u. Onkologie, Linz

A-1090

Universität f. Strahlentherape, AKH Wien, Vienna

A-4600

Klinikum Kreuzschwestern Wels GmbH, Wels

All Listed Sponsors
lead

Arbeitsgemeinschaft medikamentoese Tumortherapie

OTHER

NCT01884259 - Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN | Biotech Hunter | Biotech Hunter